Zentiva Group, a.s. announces the signing of a Business Transfer Agreement with Sanofi to acquire their manufacturing site in Ankleshwar, India. This acquisition will help ensure the continued supply of high-quality medicines to more patients by expanding the footprint and agility of Zentiva's manufacturing network.
"Expanding our network of Zentiva's wholly-owned manufacturing sites is a key factor in our future success, ensuring greater security of supply for people living in Europe and beyond. It enables us to innovate further to achieve operational excellence, enhance productivity and accelerate growth," said Nick Haggar, Chief Executive Officer of Zentiva. "We are strongly committed to the growth and success of the Ankleshwar team and operations. The site will be the largest in our network and the team in India will play a central role in the operations of Zentiva."
About Ankleshwar Manufacturing Site
Established in 1987, the site has a chemistry & biotechnology development centre, and manufactures both intermediates and pharmaceutical formulations. A large producer of tablets, the Ankleshwar site manufactures more than 6 billion tablets annually.